Allergan Aesthetics, the aesthetics unit of AbbVie Inc., was awarded $56 million in a patent infringement verdict against Nashville-based Revance Therapeutics.
A Delaware federal jury on July 18 found that Revance’s Daxxify infringed patents for Allergan’s Botox.
Daxxify, a competing product to Botox, is an injection intended to help reduce the appearance of wrinkles and frown lines.
The verdict comes four years after Allergan first sued Revance in 2021, before Daxxify was approved by the Food and Drug Administration.
